English

svenska
norsk språk
한국어
日本語
Italiano
Deutsch
Español
Pусский
Français
简体中文

PRODUCTS

Professionally provide high quality Polypeptide Modified Side Chains , Small Molecule Compounds and Advanced Excipients, LINKERs, PEGs

01

PEGS

05

Linkers

06

RNAi

ABOUT PUKANG       

Chengdu Pukang Biotechnology Co., Ltd was founded in 2008 and it is located in the national cross-strait science and technology industry development park——Cross-Strait Science and Technology Park,Wenjiang District,Chengdu,specializing in the research & development of polypeptide modifiers. As a manufacturer, it integrates production, sales, research and development. At present, our company has a R&D center of 2400 square meters, and a production workshop of 1000 square meters.
2008
Founded
2004
R & D Center
1000
Production workshop
12000
Production base
TECHNOLOGY
Chengdu Pukang is a professional manufacturer of long-acting Polypeptide Modifiers, Small Molecule Compounds,and Advanced Excipients, LINKERs, PEGs.

GOOD QUALITY，GOOD TECHNOLOGY .

Chengdu Pukang has a professional R&D team with rich experience, and innovative ideas, which can meet the various needs of customers from custom synthesis to mass production. Pukang has sufficient resources to provide process development, optimization and scale-up production. The R & D will cooperate with the production to solve the problems encountered in the pilot scale up process. We are more professional, more efficient to provide customers with high quality products.
Acquire More

BUILT FOR LIFE AND HEALTH

——————————————————————————
Polyethylene glycols is used in a wide range of biomedical applications including drug delivery, ADC conjugation, fluorescent labeling & targeted diagnostics, oligonucleotides bioconjugation, surface modification and PEGylation of protein &peptide.
View More

NEWS

Latest technology learnings and upcoming events of Pukang

长效胰岛素：即将进入每周一次新时代

长效胰岛素：即将进入每周一次新时代 转载自 Armstrong 医药笔记 2023-09-06 08:52 发表于北京▎Armstrong 2000年，甘精胰岛素获批上市，迅速成为基础胰岛素的标准疗法，并在很长时间内成为最畅销的降糖药品种。此外，由于胰岛素的治疗窗口较窄，这让更长效的胰岛素进展缓慢。不过，近年来，诺和诺德、礼来的每周一次超长效胰岛素陆续获得突破，基础胰岛素很快将进入每周一次给药的新时代。

FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) for the Treatment of Certain Hospitalized Patients with COVID-19

OLUMIANT is the first and only JAK inhibitor FDA-approved for the treatment of COVID-19 in certain hospitalized adults requiring various degrees of oxygen support.INDIANAPOLIS, May 11, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today the U.S. Food and

FDA approves Lilly's Mounjaro™ (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes

Mounjaro delivered superior A1C reductions versus all comparators in phase 3 SURPASS clinical trialsWhile not indicated for weight loss, Mounjaro led to significantly greater weight reductions versus comparators in a key secondary endpointMounjaro represents the first new class of diabetes medicines

 SERVICES

Pukang provides you with pharmaceutical services

Pukang can provide one-stop service from customer order to delivery, including the feedback of production progress, various items testing and technical documents support.

Product Testing

Technical Support

Delivery Service

Product Development

After-sales Service

Progress Feedback

About Us
Chengdu Pukang has a professional R&D team with rich experience, and innovative ideas, which can meet the various needs of customers from custom synthesis to mass production.
Quick Links
Contact Us
​​​​​​​​​​​​​​ No.288 of North Rongtai Avenue,WenJiang district 611137,Chengdu Sichuan
Province,China.
+86-28-63976226
Copyright © 2021 chengdu Pukang Biological Technology Co., Ltd.  Support By Leadong  /  Sitemap /  Private Policy